Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Sep 20, 2024
Finance
Upstream enters IPO queue; Nuvalent follow-on balloons to $575M
Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | Oct 25, 2023
Emerging Company Profile
Aiolos: going for best in class with a long-acting TSLP mAb for asthma
Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui
BioCentury | Apr 4, 2018
Translation in Brief
Targeting TSLP
How TSLP contributes to breast tumor cell growth
BioCentury | May 12, 2016
Distillery Therapeutics
Therapeutics: Thymic stromal lymphopoietin (TSLP); interleukin-33 (IL-33; NF-HEV); IL-25 (IL-17E)
Items per page:
1 - 8 of 8